Deals In Depth: June 2017
Executive Summary
In a potential $1.3 billion alliance, Merck KGAA holds options on five F-star bispecific antibodies in oncology. Two CROs, Parexel and AMRI, were taken private. Biopharma financing was up, due to public offerings, while device funding dropped due to a decline in private rounds.